May 2024 - Page 3 of 3 - BioMedWire (BMW)

FridayMay 03, 2024 10:00 am

Study Suggests Metabolism Issues After Spinal-Cord Injury Result from Disturbed Neuronal Activity

Researchers from The Ohio State University have found that disturbed neuronal activity may cause metabolism issues in individuals who suffer spinal-cord injuries. Findings from an animal study suggest that heart attacks, diabetes and vascular conditions that typically affect patients postspinal-cord injury are a result of neuronal activity that causes abdominal fat tissue compounds to start leaking and pooling into organs, such as the liver. The study also pointed to common drugs that could potentially prevent some of the metabolism issues that occur after spinal-cord injuries. The Ohio State University researchers found a connection between triglyceride breakdown in the fat tissue…

ThursdayMay 02, 2024 10:30 am

Simplifying Healthcare Appointments: How HealthLynked Corp. (HLYK) is Revolutionizing Online Booking with a Patient-Focused Approach

In an era where convenience and efficiency stand as pillars of service delivery, HealthLynked (OTCQB: HLYK) has introduced an innovative online patient booking system, akin to how OpenTable simplifies restaurant reservations. This seamless integration of technology and healthcare is transforming how patients interact with medical services, ensuring that setting up a doctor's appointment is as easy as booking a dinner date. The Booking Process: Tailored for Simplicity and Flexibility HealthLynked's online booking system is designed with the user experience at the forefront. The process is straightforward: patients select their preferred doctor, date, and whether they prefer a morning or afternoon…

WednesdayMay 01, 2024 10:00 am

Vitamin D Could Balance Gut Microbiota, Boost Cancer Immunotherapy

Vitamin D plays different roles and is easily available through the sun, meat and plants. Despite this, many individuals are vitamin D deficient. Different studies have looked into the use of vitamin D for the prevention and treatment of different cancers, including bowel, breast, skin and prostate cancer. Prior studies have linked high levels of vitamin D to decreased cancer mortality rate and reduced risk of developing cancer. In addition, researchers have explored vitamin D use in conjunction with immunotherapy. This type of treatment uses the patient’s immune system to improve its ability to eliminate cancer cells. Immunotherapy treatments include…

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…